SPLASH BEVERAGE GROUP INC (SBEV)
AMEXConsumer StaplesBeverages - Wineries & DistilleriesSnapshot 2026-09-04
$0.31-25.92%
Close 2026-08-28 · 1-day change
AMEXConsumer StaplesBeverages - Wineries & DistilleriesSnapshot 2026-09-04
QuarterlyIQ Insights · SBEV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Develop and obtain FDA regulatory approval for CannEpil veterinary applications through collaboration with Lupvindol Biosciences.
Newly stated in 2026-Q2. Management disclosed the collaboration agreement with Lupvindol to advance FDA regulatory approval for CannEpil veterinary use. No financial metrics are yet available to measure progress. The priority is newly established with initial execution underway.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Consumer Staples names rated weak grew net income 58% of the time over the next year (vs 56% for the rest of the cohort, n=2094).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“On July 31, 2026, Splash entered into a development and collaboration agreement with Lupvindol Biosciences Ltd. to lead FDA regulatory development of a CannEpil-based veterinary product.”
Maintain NYSE American listing by executing a compliance plan to regain compliance with stockholders' equity requirements.
Newly stated in 2026-Q2. Management submitted a compliance plan to NYSE American to address stockholders' equity deficiencies and maintain listing. No financial improvement metrics are provided yet. The priority is active with ongoing regulatory engagement.
“The Company submitted its NYSE compliance plan and is awaiting determination while focused on maintaining its listing.”
Acquire and commercialize pharmaceutical-grade cannabinoid products, including exclusive global licensing of CannEpil for human and veterinary use.
Newly stated in 2026-Q2. Management acquired exclusive global rights to CannEpil and expanded its use to veterinary applications. Financials show continued operating losses and no revenue growth yet, indicating early stage execution.
“In early July 2026, Splash entered into an exclusive global license for CannEpil, a pharmaceutical-grade cannabinoid platform.”
Invest capital strategically in cannabinoid-related companies and assets to support growth and diversification.
Stated in 2 disclosures during 2026-Q2. Management made a strategic investment of $217,479.24 in Avicanna and raised over $1.2 million through equity sales. Financials show ongoing operating losses and negative cash flow, indicating capital allocation is supporting operations but profitability is not yet achieved.
“Splash invested $217,479.24 and purchased shares and warrants of Avicanna Inc. in a private placement.”
“The Company sold and issued shares pursuant to Securities Purchase Agreements for gross proceeds of over $1.2 million.”
Appoint experienced executives to lead operations and support strategic transformation.
Newly stated in 2026-Q2. Management appointed a new Chief Operating Officer as part of leadership changes supporting the strategic transformation. No direct financial impact is reported yet. The priority reflects organizational strengthening.
“Michael Bondurant was appointed Chief Operating Officer to lead operations.”
Over the trailing year it converted 0.28x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
49 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Consumer Staples names rated volatile grew net income 53% of the time over the next year (vs 51% for the rest of the cohort, n=947).
Not investment advice. As of 2026-09-04.